Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Novo Nordisk

Here are two biotech stocks to watch after their recent earnings report.

2 Biotech Stocks To Watch Today Amid Earnings

Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.

Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.

Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch

Apple

AMC Entertainment

Advanced Micro Devices

Amazon

Chipotle

ConocoPhillips

Carvana

eBay

Etsy

VanEck Vectors Gold Miners ETF

GameStop

Intuitive Surgical

McDonald's

Microsoft

NVIDIA

Pinterest

QUALCOMM

Starbucks

Super Micro Computer

Snap

Spotify

Stanley Black & Decker

Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.

Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI

The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.

Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold

Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.

Moderna quarterly sales beat expectations but plummet from previous year

Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.

Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch

Moderna beat first-quarter expectations Thursday. The news could bolster Moderna stock which is approaching its first breakout in over a year.

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2024. "As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline and have intensified our focus on building and utilizing AI technologies to further streamline operations and enhance productivity," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Archer Aviation

Teladoc

For a time, Cathie Wood was the hottest investor on Wall Street. Ark Invest was bringing in billions of dollars in new assets under management.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Cathie Wood Stocks

Biohaven Pharmaceutical Hld

Gilead Sciences

Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.

Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Moderna (MRNA)

Axsome Therapeutics

Twist Bioscience Corp

Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.

3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition

Amgen

Pfizer

Regeneron Pharmaceuticals

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics

Investors have worried about Moderna's growth prospects as demand for its coronavirus vaccine declines. Moderna may have a new billion-dollar product right around the corner.

Should You Buy Moderna Before May 12?

Covid vaccine maker Moderna Inc and partner Merck Sharp and Dohme (MSD) have initiated a phase III trial in the UK for the world's first "personalised" mRNA vaccine, mRNA-4157 (V940), targeting melanoma, the deadliest form of skin cancer. Tailored to each patient's unique genetic tumour markers, the treatment aims to train the immune system to recognise and eliminate cancer cells, potentially preventing the cancer from returning.

Moderna cancer vaccine offers long-term hope in melanoma

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data related to its latent virus portfolio regarding cytomegalovirus (CMV), at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain, from April 27-30, 2024. Moderna will be presenting nine presentations at the ESCMID Global Congress, including two late-breaker oral presentations, two oral presentations, and five poster presentations: COVID-19 P0422: The mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients Poster Session, Saturday, April 27 - 12:00 (Poster area)Presenter: Bethany Girard P0553: Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: a systematic literature review and meta-analysis using the GRADE framework Poster Session, Saturday, April 27 - 12:00 (Poster area)Presenter: Ekkehard Beck OS104: Safety and immunogenicity of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine 1-hour Oral Session, Sunday, April 28 - 11:00 (Hall O)Presenter: Spyros Chalkias OS262: Demographic diversity of participants in infectious disease vaccine clinical trial 1-hour Oral Session, Tuesday, April 30 - 11:00 (Hall J)Presenter: Jameka Hill Influenza P0109: Next-generation mRNA-based seasonal influenza vaccines including additional A/H3N2 strains: Phase1/2 trial findings in adults aged 50 to 75 years Poster Session, Saturday, April 27 - 12:00 (Poster area)Presenter: Denise Hsu P0088: Consumer preferences for features of influenza vaccines in the United Kingdom: results from a discrete-choice experiment study Poster Session, Saturday, April 27 - 12:00 (Poster area)Presenter: Deborah Rudin OS235: Safety and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults 1-hour Oral Session, Monday, April 29 - 17:30 (Hall I)Presenter: Mieke Soens Respiratory Syncytial Virus (RSV) OS102: Coadministration of a respiratory syncytial virus vaccine (mRNA-1345) with an influenza or SARS-CoV-2 vaccine in older adults 1-hour Oral Session, Monday, April 29 - 11:00 (Hall C)Presenter: Jaya Goswami Cytomegalovirus (CMV) P0180: Potential relationship between cytomegalovirus and immunosenescence: evidence from observational studies Poster Session, Saturday, April 27 - 12:00 (Poster area)Presenter: John Diaz-Decaro About Moderna Moderna is a leader in the creation of the field of mRNA medicine.

Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress

Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare. Moderna is a digital-first company that has leveraged the power of machine learning since its beginnings.

Moderna and OpenAI Collaborate To Advance mRNA Medicine

Medtronic

Stryker

While artificial intelligence may be useful for a variety of purposes – including asking silly questions we're afraid to pose in real life – the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical AI stocks. When conducted in a controlled environment, AI can help accelerate productivity.

Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's (ANVISA) approval of Moderna's COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19 in children from six months of age and adults.

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.

News for Moderna Stock (MRNA)